Top 5 ELSS Funds With Up To 28% Returns In 3 Years Amid Tax-Filing Season
Top 5 ELSS Funds: ELSS funds offer tax deductions under Section 80C. Top ELSS funds include Quant, Motilal Oswal, SBI, HDFC, and Mirae Asset.
Top 5 ELSS Funds: These days, taxpayers are busy filing their income tax returns (ITR) for the financial year 2024-25 (assessment year 2025-26), with less than 30 days remaining for non-audit ones. The tax department earlier extended the due date to September 15, 2025 from July 31, 2025, keeping in mind the delay in releasing the ITR forms and related Excel utilities due to several changes in reporting income.
Meanwhile, taxpayers are ruminating on every deduction to decrease their tax liability. The old income tax regime allows taxpayers to avail these deductions. Some investments are also eligible for deductions under the old income tax regime.
Equity-Linked Savings Scheme or commonly known as ELSS allows taxpayers to not only invest in the markets but also use the investment to decrease their tax liability. ELSS is a tax-saving mutual fund that invest a minimum of 80 per cent in equities.
Taxpayers under Section 80C of the Income Tax act can avail tax deduction of up to Rs 1.5 lakh with a short lock-in period of 3 years.
Based on performance data as of August 13, 2025, here are the top five ELSS (Tax Saver) funds ranked by their 3-year returns (Direct Plan).
1. Quant ELSS Tax Saver Fund
3-Year Return: 28.82%
5-Year Return: 28.82%
NAV (Direct): Rs 399.43
3-Year Return: 25.61%
5-Year Return: 25.52%
4. HDFC ELSS Tax Saver Fund
3-Year Return: 22.08%
5-Year Return: 25.32%
NAV (Direct): Rs 1,509.65
5. Mirae Asset ELSS Tax Saver Fund
3-Year Return: 16.83%
5-Year Return: 22.37%
NAV (Direct): Rs 54.51
AUM: Rs 25,822.13 crore
view comments
First Published:
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
23 minutes ago
- News18
PM Modi To Inaugurate Rs 11,000 Cr Dwarka Expressway, UER-II Projects In Delhi Shortly
Last Updated: The 10.1 km-long Delhi section of the Dwarka Expressway has been developed at a cost of around Rs 5,360 crore. Prime Minister Narendra Modi will shortly inaugurate two National Highways projects in Delhi today. The projects—the Delhi section of the Dwarka Expressway and the Urban Extension Road-II (UER-II)—are worth Rs 11,000 crore. The Prime Minister is accompanied by Union Minister Nitin Gadkari and Delhi Chief Minister Rekha Gupta. Ahead of the inauguration, PM Modi also interacted with the construction workers. #WATCH | Delhi: Prime Minister Narendra Modi to shortly inaugurate two major National Highway projects worth a combined cost of nearly Rs 11,000 projects — the Delhi section of the Dwarka Expressway and the Urban Extension Road-II (UER-II) have been developed under… — ANI (@ANI) August 17, 2025 According to an official statement from the Prime Minister's Office, the Delhi section of the Dwarka Expressway and the Urban Extension Road-II (UER-II) are part of a comprehensive strategy aimed at reducing congestion in the capital. The statement said, 'These initiatives reflect Prime Minister Modi's vision of creating world-class infrastructure that enhances ease of living and ensures seamless mobility." The 10.1 km-long Delhi section of the Dwarka Expressway has been developed at a cost of around Rs 5,360 crore. The section will also provide multi-modal connectivity to Yashobhoomi, DMRC Blue line and Orange line, the upcoming Bijwasan railway station and the Dwarka cluster bus depot, the PMO said on Saturday in an official statement. The newly developed stretches are expected to: ⦁ Significantly improve connectivity ⦁ Reduce travel time ⦁ Ease traffic congestion in Delhi and surrounding regions The project includes: ⦁ A 5.9 km section from Shiv Murti intersection to the Road Under Bridge (RUB) at Dwarka Sector-21 ⦁ A 4.2 km section from the RUB to the Delhi-Haryana border ⦁ These stretches offer direct connectivity to the Urban Extension Road-II (UER-II) view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
an hour ago
- News18
Sebi plans review of MTF margin rules to streamline risk management
New Delhi, Aug 17 (PTI) Markets regulator Sebi is looking to review the margin framework under margin trading funding (MTF) in a bid to streamline risk management at clearing corporations. In its annual report for 2024-25, Sebi said a 'comprehensive review exercise is being undertaken with respect to the currently applicable margining framework." Alongside this, a review of MTF and the scrips eligible under it is also under consideration. Margin trading lets investors buy shares even if they do not have the full amount. They can purchase shares by paying only part of the price, while the rest is covered through a margin deposited in cash or as shares kept as collateral. In addition to the review of margin rules, Sebi is also considering changes to the regulatory framework for angel funds. The review will focus on fundraising processes, investment conditions, and operational aspects, with the objective of facilitating ease of doing business and streamlining regulatory requirements. Angel funds play a pivotal role in channelizing the capital of angel investors to startups in need of funding. Sebi has further proposed to review the classification of REITs and InvITs as hybrid instruments. This move comes in response to representations from various stakeholders, the presence of equity-like features in these instruments, the development of the market ecosystem over the last decade, and global practices. A review of the regulatory framework for mutual funds is also on the cards, aimed at ensuring that the regulations remain effective, adaptable, and aligned with the evolving market landscape. As part of this, Sebi is examining the restrictions presently prescribed for asset management companies (AMCs), after receiving feedback from the mutual funds industry, including the AMFI. In line with these efforts, Sebi intends to expand the range of permissible investment strategies under Specialised Investment Funds (SIFs). At present, SIFs allow asset management companies to offer a limited set of strategies across equity, debt, and hybrid categories. Introduced to bridge the gap between mutual funds and portfolio management services (PMS) in terms of portfolio flexibility, the SIF framework requires investors to commit at least Rs 10 lakh across all SIF strategies. PTI SP DRR view comments First Published: August 17, 2025, 11:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
News18
an hour ago
- News18
Aurobindo Pharma expects China plant to break even at EBITDA level this year
Agency: PTI New Delhi, Aug 17 (PTI) Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. 'This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around USD 30 million in the Biologics CMO business so far, and the balance of USD 100 million plus capital is expected to be invested by March 2027. Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. 'We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to Rs 824 crore for the June quarter, due to a fall in sales in the US and API business vertical. Its revenue from operations increased to Rs 7,868 crore for the June quarter against Rs 7,567 crore in the year-ago period. PTI MSS BAL BAL view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
